Growing evidence identified GPNMB as an attractive therapeutic target for tumor and cancer (Swanton and Jones, 2001; He et al., 2002; Laichalk and Thorley-Lawson, 2005; Grey et al., 2010; Balistreri et al., 2016). The gene discussed is GPNMB; the disease is cancer.